跳至主要内容
临床试验/NCT07179887
NCT07179887招募中不适用

Remote Ischaemic Conditioning in the Older Person and Effects on Dynamic Cerebral Autoregulation

University of Nottingham1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2025年8月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
45
试验地点
1
主要终点
Autoregulatory Index

研究概览

简要总结

Remote Ischaemic Conditioning (RIC) is the process of inducing short periods of ischaemia in a limb with the aim of improving vascular health systemically. Recent findings have demonsatrated efficacy in a variety of clinical settings. However, the ideal protocol of RIC [dose] is unknown. Dynamic Cerebral Autoregulation (dCA) has been shown to increase in response to RIC.

The goal of this trial is to study whether an increase in RIC protocol intensity results in a larger effect on biomarkers of vascular health such as dCA.

Participants shall:

Receive RIC daily, RIC thrice weekly or sham RIC thrice weekly for 6 weeks Visit the School of Medicine at baseline and at 6 weeks for measurement of biomarkers of vascular health including blood pressure, indices od dCA and blood plasma samples

详细描述

Remote Ischaemic Conditioning (RIC) involves the delivery of short periods of ischaemia to a limb (using a blood pressure cuff), with the aim of promoting resilience to ischaemia in distant organs. It has shown promise as in intervention in both the treatment of acute ischaemic stroke and secondary prevention of cerebrovascular events. Various protocols exist ranging from single sessions of RIC delivered around the time of an ischaemic event, known as acute RIC, to repeated sessions delivered over days, weeks or even months, known as chronic RIC.

Preclinical work in animal models of stroke demonstrated consistent benefits of RIC. However, translation of these findings to human trials has yielded mixed results. Two large randomised controlled trials conducted in recent years have suggested benefit where RIC is given as a treatment following acute ischaemic stroke or when used in the secondary prevention of stroke in patients with symptomatic intracranial atherosclerosis. However, other clinical trials of RIC have yielded neutral results. For example, the RESIST trial, which used RIC as an intervention following both acute ischaemic and haemorrhagic stroke.

It is not known exactly why the promising findings in preclinical studies have not been replicated in human trials. It is likely that protocols of RIC, i.e. the 'dose', which proved effective in animal models of stroke, may not be sufficient when applied to multimorbid human populations who have also received current standard therapy. These therapies, such as antiplatelets, themselves provide cerebrovascular protection and may abrogate some of the benefit of RIC. It may be that more intense protocols of RIC, particularly chronic RIC, are needed to illicit benefit in humans.

To answer this question, work should be done to investigate the effect of RIC protocol intensity on vascular health in older adults. Too often in RIC research, there has been a rapid jump from preclinical study to large RCT. These RCTs initially used protocols of RIC based on those used in preclinical studies. With increasing awareness of the potential problems with this approach, RCTs now tend to use more intense protocols of RIC. However, very little work has been done examining the effect of RIC on biomarkers of vascular health to inform the choice of RIC dose, informing future trial design.

Dynamic cerebral autoregulation (dCA) is a measure of the regulation of cerebral blood flow in response to changes in systemic blood pressure. It has been shown to be impaired in the immediate post stroke period (≈2 weeks) and severely impaired autoregulation in the hours after stroke has been correlated with worse outcomes. Dynamic Cerebral Autoregulation has also been shown to improve in young adults given 2 weeks of RIC. We propose to conduct a further study in older adults, aged 65-85, investigating the effect of chronic RIC on biomarkers of vascular health including dCA and blood pressure (BP), comparing two difference dosing regimens.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Participant is willing and able to give informed consent for participation in the study
  • •Participant aged 65 - 85
  • •Participant is able to perform RIC independently at home

排除标准

  • •Active cardiovascular or cerebrovascular disease (acute event within the last 12 months)
  • •Atrial fibrillation or other significant arrhythmias
  • •Peripheral Vascular Disease
  • •Haemostatic disorders
  • •Soft tissue injury or fracture to the upper limb
  • •Pregnant or breast feeding
  • •History or current psychiatric illness
  • •History or current neurological condition (e.g. epilepsy)
  • •Inability to identify temporal window for transcranial doppler ultrasound at screening visit
  • •Any condition or presentation under current investigation that is deemed by the study clinician to exclude the participant from the study.
  • •Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

研究组 & 干预措施

High dose RIC

Experimental

Daily sessions of RIC for 6 weeks. Each session will consist of 4 x 5 minute cuff inflation to 20mmHg above systolic blood pressure, interspersed with 5 minute periods of cuff deflation

干预措施: Remote Ischaemic Conditioning (Device)

Low dose RIC

Experimental

3x weekly sessions of RIC for 6 weeks. Each session will consist of 4 x 5 minute cuff inflation to 20mmHg above systolic blood pressure, interspersed with 5 minute periods of cuff deflation

干预措施: Remote Ischaemic Conditioning (Device)

Sham RIC

Placebo Comparator

3x weekly sessions of Sham RIC for 6 weeks. Each session will consist of 4 x 5 minute cuff inflation to 20mmHg only, interspersed with 5 minute periods of cuff deflation

干预措施: Sham Remote Ischaemic Conditioning (Device)

结局指标

主要结局

Autoregulatory Index

时间窗: Baseline and 6 weeks

In dynamic cerebral autoregulation analysis, the Autoregulatory Index is a dimensionless index ranging from 0 to 9. 0 represents no autoregulation and 9 represents very strong autoregulation

次要结局

  • Phase DIfference(Baseline and 6 weeks)
  • Gain(Baseline and 6 weeks)
  • Clinic Systolic Blood Pressure(Baseline and week 6)
  • Clinic Diastolic Blood Pressure(Baseline to 6 Weeks)
  • Clinic Mean Arterial Pressure(Baseline to 6 Weeks)
  • Blood plasma markers(Baseline and 6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Timothy England

Professor of Stroke Medicine

University of Nottingham

研究点 (1)

Loading locations...

相似试验